A Phase 1/2, Open-Label, Dose-Escalation And Expansion Study Of Entrectinib (Rxdx-101) In Pediatrics With Locally Advanced Or Metastatic Solid Or Primary CNS Tumours And/Or Who Have No Satisfactory Treatment Options
This is an open-label, Phase 1/2 multicentre dose escalation study in pediatric patients with relapsed or refractory extracranial solid tumours (Phase 1), with additional expansion cohorts (Phase 2) in patients with primary brain tumours harboring NTRK1/2/3 or ROS1 gene fusions, and extracranial solid tumours harboring NTRK1/2/3 or ROS1 gene fusions.
Primary Outcome:
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the Canadian Cancer Society